RAGE in inflammation

A new therapeutic target?

Angelika Bierhaus, David Stern, Peter P. Nawroth

Research output: Contribution to journalReview article

134 Citations (Scopus)

Abstract

High-molecular group box 1-protein, S100/calgranulins, advanced glycation end products (AGES), amyloid-β peptides and the family of β-sheet fibrils contribute to a number of inflammatory conditions by promoting cellular dysfunction and breaking immune tolerance. The receptor of AGE (RAGE) is a multiligand receptor of the immunoglobulin superfamily of cell surface molecules that acts as a pattern recognition receptor. Besides binding ligands actively participating in inflammation and immune responses, RAGE serves as an endothelial adhesion receptor for leukocyte integrins and promotes leukocyte recruitment and extravasation of infiltrating cells. Engagement of RAGE subsequently converts transient cellular stimulation into sustained cellular dysfunction driven by long-term activation of the proinflammatory nuclear factor-κB. Deletion of RAGE and pharmacological interventions targeting interruption of RAGE-ligand interaction suppresses inflammation and dampens tissue damage in experimental models of inflammatory disorders, thus delineating RAGE as a potential therapeutic target in inflammation.

Original languageEnglish (US)
Pages (from-to)985-991
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Volume7
Issue number11
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Inflammation
Leukocyte-Adhesion Receptors
Therapeutics
Leukocyte L1 Antigen Complex
Ligands
Pattern Recognition Receptors
Immune Tolerance
Advanced Glycosylation End Products
S100 Proteins
Amyloid
Integrins
Advanced Glycosylation End Product-Specific Receptor
Immunoglobulins
Leukocytes
Theoretical Models
Pharmacology
Peptides

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

RAGE in inflammation : A new therapeutic target? / Bierhaus, Angelika; Stern, David; Nawroth, Peter P.

In: Current Opinion in Investigational Drugs, Vol. 7, No. 11, 01.11.2006, p. 985-991.

Research output: Contribution to journalReview article

Bierhaus, A, Stern, D & Nawroth, PP 2006, 'RAGE in inflammation: A new therapeutic target?', Current Opinion in Investigational Drugs, vol. 7, no. 11, pp. 985-991.
Bierhaus, Angelika ; Stern, David ; Nawroth, Peter P. / RAGE in inflammation : A new therapeutic target?. In: Current Opinion in Investigational Drugs. 2006 ; Vol. 7, No. 11. pp. 985-991.
@article{84e492f0efef443997727bf8ca1b01a4,
title = "RAGE in inflammation: A new therapeutic target?",
abstract = "High-molecular group box 1-protein, S100/calgranulins, advanced glycation end products (AGES), amyloid-β peptides and the family of β-sheet fibrils contribute to a number of inflammatory conditions by promoting cellular dysfunction and breaking immune tolerance. The receptor of AGE (RAGE) is a multiligand receptor of the immunoglobulin superfamily of cell surface molecules that acts as a pattern recognition receptor. Besides binding ligands actively participating in inflammation and immune responses, RAGE serves as an endothelial adhesion receptor for leukocyte integrins and promotes leukocyte recruitment and extravasation of infiltrating cells. Engagement of RAGE subsequently converts transient cellular stimulation into sustained cellular dysfunction driven by long-term activation of the proinflammatory nuclear factor-κB. Deletion of RAGE and pharmacological interventions targeting interruption of RAGE-ligand interaction suppresses inflammation and dampens tissue damage in experimental models of inflammatory disorders, thus delineating RAGE as a potential therapeutic target in inflammation.",
author = "Angelika Bierhaus and David Stern and Nawroth, {Peter P.}",
year = "2006",
month = "11",
day = "1",
language = "English (US)",
volume = "7",
pages = "985--991",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "11",

}

TY - JOUR

T1 - RAGE in inflammation

T2 - A new therapeutic target?

AU - Bierhaus, Angelika

AU - Stern, David

AU - Nawroth, Peter P.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - High-molecular group box 1-protein, S100/calgranulins, advanced glycation end products (AGES), amyloid-β peptides and the family of β-sheet fibrils contribute to a number of inflammatory conditions by promoting cellular dysfunction and breaking immune tolerance. The receptor of AGE (RAGE) is a multiligand receptor of the immunoglobulin superfamily of cell surface molecules that acts as a pattern recognition receptor. Besides binding ligands actively participating in inflammation and immune responses, RAGE serves as an endothelial adhesion receptor for leukocyte integrins and promotes leukocyte recruitment and extravasation of infiltrating cells. Engagement of RAGE subsequently converts transient cellular stimulation into sustained cellular dysfunction driven by long-term activation of the proinflammatory nuclear factor-κB. Deletion of RAGE and pharmacological interventions targeting interruption of RAGE-ligand interaction suppresses inflammation and dampens tissue damage in experimental models of inflammatory disorders, thus delineating RAGE as a potential therapeutic target in inflammation.

AB - High-molecular group box 1-protein, S100/calgranulins, advanced glycation end products (AGES), amyloid-β peptides and the family of β-sheet fibrils contribute to a number of inflammatory conditions by promoting cellular dysfunction and breaking immune tolerance. The receptor of AGE (RAGE) is a multiligand receptor of the immunoglobulin superfamily of cell surface molecules that acts as a pattern recognition receptor. Besides binding ligands actively participating in inflammation and immune responses, RAGE serves as an endothelial adhesion receptor for leukocyte integrins and promotes leukocyte recruitment and extravasation of infiltrating cells. Engagement of RAGE subsequently converts transient cellular stimulation into sustained cellular dysfunction driven by long-term activation of the proinflammatory nuclear factor-κB. Deletion of RAGE and pharmacological interventions targeting interruption of RAGE-ligand interaction suppresses inflammation and dampens tissue damage in experimental models of inflammatory disorders, thus delineating RAGE as a potential therapeutic target in inflammation.

UR - http://www.scopus.com/inward/record.url?scp=33751026851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751026851&partnerID=8YFLogxK

M3 - Review article

VL - 7

SP - 985

EP - 991

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 11

ER -